Based in Hong Kong, we are home to some of the world’s most intrepid scientists from the world’s top university, with a proven track record of success in drug discovery and development.

Based in Hong Kong, we are home to some of the world’s most intrepid scientists from the world’s top university, with a proven track record of success in drug discovery and development.

In 2016, we have completed the research and development of PROHEP microbial mixture, the only innovative drug in the global microbial field that can prevent and treat HCC, and has obtained global patent technology protection.

In 2022, Prohep has made breakthrough progress in the research of non-alcoholic fatty liver disease, colorectal cancer and other fields, applying for global patent protection right now.

In 2023, Prohep has completed the formula of health care products with hypoglycemic function for diabetic patients. It is expected to be launched on the market in June 2024, with obvious blood sugar-lowering effects.

In the later stage, our products are targeting hyperlipidemia, non-alcoholic fatty liver disease, children’s anti-allergy, etc.